Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
AssigneeFred Hutchinson Cancer Research Center
InventorsCarla Grandori, Masafumi Toyoshima
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.
Claims21
A method for inhibiting the growth and/or proliferation of a cisplatin resistant ovarian tumor cell having an amplified c-myc gene, comprising the step of contacting the cisplatin resistant ovarian tumor cell having the amplified c-myc gene with a casein kinase 1 epsilon (CSNK1ε) inhibitor.
A method of treating a subject suffering from a cisplatin resistant ovarian tumor comprising cisplatin resistant ovarian tumor cells having an amplified c-myc gene, comprising administering to the subject an amount of a composition comprising a casein kinase 1 epsilon (CSNK1ε) inhibitor effective to inhibit the growth and/or proliferation of the cisplatin resistant ovarian tumor cells having the amplified c-myc gene.
A method of treating cisplatin resistance in ovarian tumor cells comprising the steps of:
- (i) determining whether said tumor cells overexpress c-Myc and (ii) subsequently administering an effective amount of a casein kinase 1 epsilon (CSNK1ε) inhibitor to said cisplatin resistant ovarian tumor cells.
A method of treating cisplatin resistance in ovarian tumor cells comprising the steps of:
- (i) determining whether said tumor cells have an amplified c-myc gene and (ii) subsequently administering an effective amount of a casein kinase 1 epsilon (CSNK1ε) inhibitor to said cisplatin resistant ovarian tumor cells.
Dependencies are inferred from the claim text.